| Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors R Keshet, JS Lee, L Adler, M Iraqi, Y Ariav, LQJ Lim, S Lerner, ... Nature Cancer 1 (9), 894-908, 2020 | 49 | 2020 |
| SCAPER localizes to primary cilia and its mutation affects cilia length, causing Bardet-Biedl syndrome O Wormser, L Gradstein, Y Yogev, Y Perez, R Kadir, I Goliand, Y Sadka, ... European Journal of Human Genetics 27 (6), 928-940, 2019 | 42 | 2019 |
| The Ebola-glycoprotein modulates the function of natural killer cells A Edri, A Shemesh, M Iraqi, O Matalon, M Brusilovsky, U Hadad, ... Frontiers in immunology 9, 1428, 2018 | 23 | 2018 |
| Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity A Ottolenghi, P Bolel, R Sarkar, Y Greenshpan, M Iraqi, S Ghosh, ... Scientific Reports 11 (1), 7676, 2021 | 18 | 2021 |
| Nanowire based mechanostimulating platform for tunable activation of natural killer cells V Bhingardive, A Edri, A Kossover, GL Saux, B Khand, O Radinsky, ... Advanced Functional Materials 31 (26), 2103063, 2021 | 17 | 2021 |
| N-Glycans mediate the ebola virus-GP1 shielding of ligands to immune receptors and immune evasion M Iraqi, A Edri, Y Greenshpan, K Kundu, P Bolel, A Cahana, A Ottolenghi, ... Frontiers in cellular and infection microbiology 10, 48, 2020 | 15 | 2020 |
| Antibody-functionalized nanowires: a tuner for the activation of T cells V Bhingardive, A Kossover, M Iraqi, B Khand, G Le Saux, A Porgador, ... Nano Letters 21 (10), 4241-4248, 2021 | 13 | 2021 |
| Crizotinib in MET exon 14-mutated or MET-amplified in advanced disease non-small cell lung cancer: a retrospective, single institution experience W Shalata, A Yakobson, S Weissmann, E Oscar, M Iraqi, W Kian, N Peled, ... Oncology 100 (9), 467-474, 2022 | 10 | 2022 |
| Rapid response to the combination of lenvatinib and pembrolizumab in patients with advanced carcinomas (Lung adenocarcinoma and malignant pleural mesothelioma) W Shalata, M Iraqi, B Bhattacharya, V Fuchs, LC Roisman, AY Cohen, ... Cancers 13 (14), 3630, 2021 | 8 | 2021 |
| CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma E Remer, M Badarni, E Hikri, A Dayan, L Levi, A Popovtzer, M Iraqi, ... Journal of Clinical Medicine 9 (10), 3214, 2020 | 7 | 2020 |
| Blocking the PCNA/NKp44 checkpoint to stimulate NK cell responses to multiple myeloma M Iraqi, A Edri, Y Greenshpan, O Goldstein, N Ofir, P Bolel, M Abu Ahmad, ... International Journal of Molecular Sciences 23 (9), 4717, 2022 | 5 | 2022 |
| Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination W Shalata, D Levin, J Fridman, V Makarov, M Iraqi, M Golosky, ... Current Oncology 29 (2), 989-1000, 2022 | 3 | 2022 |
| Multifunctional Nanoscale Platform for the Study of T Cell Receptor Segregation E Toledo, M Iraqi, A Pandey, S Tzadka, G Le Saux, A Porgador, ... ACS omega 8 (32), 28968-28975, 2023 | 1 | 2023 |
| Elastic Microstructures: Combining Biochemical, Mechanical, and Topographical Cues for the Effective Activation and Proliferation of Cytotoxic T Cells A Pandey, M Iraqi, E Toledo, A Al-Kader Yassin, E Podvalni, S Naaz, ... ACS applied materials & interfaces 15 (26), 31103-31113, 2023 | 1 | 2023 |
| NKp44-derived peptide used in combination stimulates antineoplastic efficacy of targeted therapeutic drugs M Iraqi, P Bolel, R Sarkar, B Bhattacharya, M Abu Ahmad, A Edri, ... International Journal of Molecular Sciences 23 (22), 14054, 2022 | 1 | 2022 |
